Anavex Life Sciences Corp (AVXL)

[georgejjl]

Near term catalysts that will create an upward jump in AVXL stock value

Alzheimer’s disease: Data from the blarcamesine Phase
2b/3 ANAVEX®2-73-AD-004 trial to be published in an
upcoming peer-reviewed journal

Alzheimer’s disease: Full regulatory submission of
blarcamesine in Europe (EMA)

Alzheimer’s disease: Analysis of RNA sequencing (RNA-
seq) of the Phase 2b/3 data expected 2H 2024

Alzheimer’s disease: Ongoing ATTENTION-AD OLE 96-
week trial data expected 2H 2024

Schizophrenia: Top-line data of ANAVEX®3-71 Phase 2
clinical trial

Parkinson’s disease: Initiation of ANAVEX®2-73 imaging-
focused trial or Phase 2b/3 >6 months trial

Fragile X: Initiation of ANAVEX®2-73 Phase 2/3 clinical trial

New Rare disease: Initiation of ANAVEX®2-73 Phase 2/3
clinical trial

Publications: Continued clinical publications involving
ANAVEX®2-73 and ANAVEX®3-71

Good luck and GOD bless,